32
Pharma & HealthcareAvoid
Nippon India Pharma
Nippon India · Direct–Growth · rank #14 of 19 by Smart Score
Data updated
Trailing returns
1 Year
5.6%
+10.3% vs index
3 Years
16.4%
+7.1% vs index
5 Years
12.5%
+4.6% vs index
Since launch
16.9%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-9.1%-12.9% vs index
2023
+40.4%+13.8% vs index
2024
+35.3%+19.6% vs index
2025
-2.5%-10.1% vs index
2026
+6.0%+12.1% vs index
Why this score
Nippon India Pharma scores 32/100 — #14 of 19 Pharma & Healthcare fund (Avoid). It stands out for fund size — beating 97% of peers on fund size. The main drag is its 3y return (better than only 4% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return16.42% · 4th percentile in category
5Y return12.46% · 17th percentile in category
Fund size9166.40 Cr · 97th percentile in category
Alpha1.09 · 9th percentile in category
Sharpe ratio0.81 · 31st percentile in category
1Y return5.57% · 15th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd11.71%
2.Divi's Laboratories Ltd7.1%
3.Lupin Ltd6.17%
4.Cipla Ltd6.01%
5.Dr. Reddy's Laboratories Ltd5.45%
36 disclosed equity positions · portfolio as of Sept 2026 · weights are % of total corpus.